The future of hybrid operating rooms still lies in DSA.
Hybrid Operating Room
Balloon dilation + thorn penetration dual mechanism
Reflow Medical’s Spur Stent System is the first retrievable peripheral stent system approved by the FDA via the De Novo pathway in May 2025. It is designed to treat primary or restenosis of the below-knee artery (BTK) and is indicated for patients with chronic limb-threatening ischemia (CLTI).
Adjustable double balloon catheter
RenovoCath is an FDA-approved, innovative dual-balloon catheter drug delivery system developed by RenovoRx, serving as the core device of its transarterial microperfusion therapy platform.
InVera’s innovative mechanical ablation catheter for varicose vein treatment
InVera Medical’s InVera Infusion Device is an innovative non-thermal ablation catheter system for chronic venous disease (CVD), which received FDA 510(k) approval in April 2026, prior to which it had already obtained EU CE certification. The device is designed for minimally invasive treatment of conditions such as varicose veins in the lower extremities.
Stirring + Suction: Dual Mechanism for Pulmonary Embolism
The Hēlo Thrombectomy System, developed by Endovascular Engineering (E2), is a next-generation mechanical thrombectomy platform designed specifically for the treatment of pulmonary embolism (PE). Its core technology employs a patented dual-effect mechanism that combines aspiration with mechanical thrombus destruction.
Stryker announces acquisition of AVS
Stryker announces acquisition of AVS, making a strong entry into the intravascular shockwave lithotripsy track.
A Decade of Changes in Interventional Treatment of Acute Pulmonary Embolism3
A Decade of Changes in Interventional Treatment of Acute Pulmonary Embolism
Serenity’s River stent
On March 31, 2026, Serenity Medical, a subsidiary of NeuroTechnology Investors (NTI), announced that its River stent had received Humanitarian Device Exemption (HDE) approval from the U.S. FDA. This is the world’s first and currently the only FDA-approved stent specifically designed for intracranial venous sinuses, targeting refractory idiopathic intracranial hypertension (IIH), filling a treatment gap in this field.
River, the world’s first stent specifically designed for cerebral veins, has been approved by the FDA.
On March 31, 2026, Serenity Medical announced that its self-developed River cerebral vein stent received Humanitarian Device Exemption (HDE) approval from the U.S. FDA, becoming the world’s first stent system designed for the cerebral venous system to receive FDA approval. This milestone marks a new stage in cerebral venous interventional therapy, providing an important treatment option for patients with idiopathic intracranial hypertension (IIH).
Neurointervention + thrombus aspiration + promising future
“Neurointervention + thrombus aspiration + promising future”: This innovative medical device deserves attention.
